RT Journal Article
SR Electronic
T1 Potential of phenothiazines to synergistically block calmodulin and reactivate PP2A in cancer cells
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2021.06.16.448716
DO 10.1101/2021.06.16.448716
A1 Okutachi, Sunday
A1 Manoharan, Ganesh babu
A1 Abankwa, Daniel
YR 2021
UL http://biorxiv.org/content/early/2021/06/17/2021.06.16.448716.abstract
AB Phenothiazines (PTZ) are well known as inhibitors of monoamine neurotransmitter receptors, notably dopamine receptors. Because of this activity they are used for decades as antipsychotic drugs. In addition, significant anti-cancer properties have been ascribed to them. Several attempts for their repurposing were made, however, their incompletely understood polypharmacology is challenging.Here we examined the potential of PTZ to synergistically act on two cancer associated targets, calmodulin (CaM) and the tumor suppressor protein phosphatase 2A (PP2A). Both proteins are known to modulate the Ras-MAPK pathway activity. Consistently, combinations of a CaM inhibitor and a PP2A activator synergistically inhibited cancer cells with KRAS or BRAF mutations. We identified the covalently reactive PTZ derivative fluphenazine mustard as an inhibitor of Ras driven proliferation and Ras membrane organization. We confirmed its anti-CaM activity in vitro and through a cellular CaM target engagement bioluminescence resonance energy transfer (BRET) assay. Our results suggest that improved PTZ derivatives retaining their synergistic CaM inhibitory and PP2A activating properties, but without neurological side-effects, may be interesting to pursue further as anti-cancer agents.